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Strengths and limitations of this study
 ► The Australian Contraceptive ChOice pRoject 
(ACCORd) successfully trialled a complex practice- 
based intervention to improve the uptake of long- 
acting reversible contraception among Australian 
women.
 ► A longitudinal 3- year follow- up of the ACCORd Study 
will be conducted via an online survey to assess 
the long- term acceptability, effectiveness and cost- 
effectiveness of the intervention.
 ► The trial was conducted in metropolitan Melbourne; 
consequently, the participating general practitioners 
and women may not be representative of the broad-
er Australian population.
AbStrACt
Introduction Through addressing main barriers to the 
uptake of long- acting reversible contraceptives (LARCs) 
among Australian women, the Australian Contraceptive 
ChOice pRoject (ACCORd) trialled an educational 
intervention targeting general practitioners (GPs) and 
provided those in the intervention group with a rapid 
referral service for quick insertion. The cluster randomised 
controlled trial resulted in greater uptake of LARC in 
the intervention group. This protocol paper describes a 
longitudinal follow- up to the ACCORd Study to assess 
the long- term efficacy and cost- effectiveness of the 
intervention.
Methods and analysis Women participants (patients 
of ACCORd GPs) completed a baseline, 6- month and 
12- month survey. These participants will be invited to 
complete an additional follow- up survey 3 years post 
completion of their baseline interview. Based on the 
original ACCORd Study tools, the online survey will address 
long- term outcomes including contraceptive continuation 
rates and reproductive history, any unintended 
pregnancies, satisfaction and concerns with their current 
contraceptive method, and an assessment of quality of 
life. We will analyse data using binary regression models 
with generalised estimating equations and robust standard 
errors to account for clustering.
Discussion Demonstration of sustained use, effectiveness 
at reducing unwanted pregnancies and cost- effectiveness 
of this strategy among this cohort of Australian primary 
care patients, will strengthen the policy and programme 
urgency of addressing wider dissemination of these 
strategies and replicating the study elsewhere.
Ethics and dissemination The ACCORd Study received 
approval from the Monash University Human Research 
Ethics Committee: CF16/188-201000080. Additionally, an 
amendment to conduct this 3- year longitudinal follow- up 
survey has been approved. The trial follow- up outcomes 
will be disseminated through formal academic pathways, 
including journal articles, national and international 
conferences and reports as well as using more 
‘mainstream’ strategies such as seminars, workshops 
and media engagement. Additionally, outcomes will be 
communicated through policy briefs to Australian state and 
federal governments.
trail registration number This trial is registered 
with the Australian and New Zealand Trials Registry 
ACTRN12615001346561. Recruitment and data collection 
have been completed for the baseline, 6- month and 
12- month surveys. Data collection for the 3- year survey 
commenced in August 2019.
IntroDuCtIon
In an effort to reduce rates of unintended 
pregnancies in Australia, the Australian 
Healthcare and Hospitals Association has 
expressed the need for more research into 
the barriers as well as the facilitators of 
long- acting reversible contraceptive (LARC) 
uptake, including intrauterine devices and 
implants.1 The Australian Contraceptive 
ChOice pRoject (ACCORd)2 3 is an Australian 
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adaptation of the successful Contraceptive CHOICE 
Project (CHOICE)4 conducted in the USA, and is the 
first study in Australia to evaluate whether a complex 
intervention in general practice settings resulted in 
increased LARC uptake among women. The ACCORd 
intervention involved training general practitioner (GPs) 
to deliver efficacy- focused contraceptive counselling as 
well as providing a rapid referral pathway for insertion 
of LARCs. In the control group, GPs provided usual 
care contraceptive counselling; they did not receive any 
training and were not given access to a rapid referral 
pathway for LARC insertion. The ACCORd Study aimed 
to address patient, practitioner and system barriers in 
order to increase the uptake of LARCs and reduce rates 
of unintended pregnancy.
The ACCORd intervention resulted in increased 
LARC uptake among women. Within 4 weeks of receiving 
contraceptive counselling during a GP consultation, 
19.3% of women in the intervention group had an LARC 
inserted, compared with 12.9% in the control group. At 
6 months and 12 months post baseline, a significantly 
greater proportion of participants in the intervention 
group were using an LARC compared with the control 
group. Notably, no differential effects were found for age, 
parity, use of LARC at baseline, marital status, socioeco-
nomic status, education, previous unintended pregnancy 
or previous abortion.2
While the findings of the ACCORd Study are prom-
ising, the 6- month and 12- month follow- up timeline 
provides little insight into the long- term sustained impact 
of the intervention. In the US CHOICE Study, a follow- up 
survey was conducted every 6 months up to 3 years post 
enrolment. More than 9000 women participated in the 
CHOICE Study and the intervention resulted in a signif-
icant increase in the uptake of LARCs. At 12- month and 
24- month LARC users reported greater continuation 
rates of their chosen contraceptive method (87% at 12 
months, 77% at 24 months) than non- LARC users (57% 
at 12 months, 41% at 24 months).5 Consequently, the 
researchers observed a reduction in teen pregnancy, 
birth and abortion in the St Louis region, (the site of the 
CHOICE Study), compared with the national rates among 
sexually active teens.6 At 3 years, the CHOICE Study again 
found impressive continuation rates for LARC methods 
(67.2%) compared with non- LARC methods (31%).7
We are yet to examine similar longitudinal data 
in the Australian context. While the ACCORd Study 
has not involved 6- monthly follow- ups, a longitudinal 
follow- up (3 years from baseline) of the participants of 
the ACCORd Study will provide an understanding of the 
longer- term outcomes of the ACCORd intervention. This 
follow- up study will further evaluate the effectiveness and 
cost- effectiveness of the intervention in increasing LARC 
uptake, sustaining its use and decreasing unplanned 
pregnancies. Specifically, the longitudinal follow- up will 
examine the continuation rate of contraceptive method 
chosen, particularly comparing LARC to non- LARC 
methods; current contraceptive methods used by women 
in the intervention compared with the control group; and 
a comparison of incidents of unintended pregnancy and 
abortion since the previous survey between LARC and 
non- LARC users. In addition, a cost- effectiveness evalua-
tion of the intervention will be conducted.
MEthoDS AnD trIAl DESIgn
the ACCord Study
The ACCORd Trial was a cluster randomised controlled 
trial set in metropolitan Melbourne, Australia, using GPs 
as the unit of randomisation. Twenty- five intervention 
GPs and thirty- two control GPs participated in the study. 
Only one GP per clinic was included in the study in order 
to avoid contamination due to cross- over effects and the 
clinic reception staff assisted with recruiting the patient 
participants.
Women attending the clinic were invited by the recep-
tion staff to complete an online eligibility survey on an 
iPad in the clinic waiting room. Women were eligible to 
participate if they were between 16 and 45 years old, had 
been sexually active with a male partner in the previous 
6 months or anticipated sexual activity in the following 
6 months, had not undergone tubal ligation or hysterec-
tomy, had sexual partners who had not undergone a vasec-
tomy, were neither pregnant or anticipating a pregnancy 
in the following 12 months, spoke proficient English and 
were interested in discussing contraception or in starting 
a new, reversible contraceptive method.
Contact details were recorded with the eligibility survey 
and all eligible women were contacted by phone by an 
ACCORd researcher to obtain consent and complete 
baseline questionnaires. Women were asked to make 
an appointment with their ACCORd GP for contracep-
tive counselling within 1 week of their enrolment. Addi-
tional charges for these appointments were covered by 
ACCORd to ensure that the participants did not bear any 
out- of- pocket expenses for the additional visit.
The GPs who were allocated to the intervention group 
underwent training to deliver structured contraceptive 
counselling8 consisting of non- biassed, scripted descrip-
tions of all available contraceptive methods, with a partic-
ular focus on the efficacy and safety of each method. The 
intervention GPs were also given access to rapid referral 
LARC insertion clinics via an online booking system.
The intervention GPs delivered the structured contra-
ceptive counselling to the participating women as well as 
collected clinical information from the women to identify 
any contraindications or conditions that may influence 
the choice of contraception. Women were then able to 
choose their preferred method, provided that it was not 
medically contraindicated. The GP was also advised to 
screen for pregnancy, including history and a urine test, 
and for Chlamydia trachomatis (according to clinical prac-
tice guidelines published by the Royal Australian College 
of General Practitioners).9
In the instance where a woman chose an LARC method, 
intervention GPs could book an appointment for the 
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woman via the online rapid referral system to an LARC 
insertion clinic with a local gynaecologist. Two gynaecolo-
gist practices were involved in the study. One of the gynae-
cologists was female and charged fees for insertion; the 
other was male and charged no out- of- pocket expenses.
The GPs in the control group were required to provide 
usual care to women allocated to this group. The control 
group was neither given access to the educational inter-
vention nor to the rapid referral LARC insertion clinics.
Women were eligible to participate in the ACCORd 
Study if they were 16–45 years old, had been sexually 
active with a male partner in the previous 6 months or 
anticipated sexual activity in the following 6 months, had 
not undergone tubal ligation or hysterectomy, had sexual 
partners who had not undergone vasectomy, were neither 
pregnant nor anticipating a pregnancy in the next 12 
months, spoke proficient English and were interested in 
discussing contraception or in starting a new reversible 
contraceptive method. Participating women were asked 
to complete follow- up surveys online at 6 and 12 months 
after enrolment in the study. Baseline, 6- month and 
12- month surveys involved a questionnaire adapted from 
the US Contraceptive CHOICE Project (CHOICE)5 and 
included the Health Literacy Questionnaire10 at baseline 
and 6 months, and Medical Outcomes Survey (SF-36)11 at 
baseline, 6 and 12 months.
ACCord longitudinal study for the 3-year follow-up
Recruitment
Women who participated in the original ACCORd Study 
will be invited to complete an additional online survey as 
close as possible to the 3- year anniversary of completing 
their original baseline assessment. Additional consent will 
be obtained via an online form at the beginning of the 
online survey, following an explanatory statement.
Participants will be emailed with an invitation to take 
part in the ACCORd 3- year follow- up survey. The email 
will include a link to the Research Electronic Data Capture 
(REDCap) Survey. A follow- up phone call will be made 
to confirm receipt of the email and to gently remind 
women to complete the survey if they wish to, addition-
ally providing the option to complete the survey as a tele-
phone interview. Text message reminders will also be sent 
if women are yet to complete the survey. Compensation 
for time of $30 in the form of an online gift card will be 
offered to women for completing the survey. Participants 
will be recruited for the 3- year follow- up survey from 
August 2019 until August 2020.
Sample size
A total of 740 women participated in the ACCORd Study. 
For the 3- year follow- up we will be inviting all partici-
pants who completed the baseline survey and did not 
actively withdraw from the study (n=705). Based on a 
71% response rate at both the 6- month and 12- month 
follow- up, a similar response rate for the 3- year follow- up 
is expected.
Outcome measures
The 3- year survey will involve an adapted version of the 
ACCORd 12- month survey, as well as the SF-36 to measure 
participants’ quality of life. During the survey, women will 
be asked to report on their current contraceptive use as 
well as providing an indication of their satisfaction with the 
contraceptive method on a 3- point Likert scale ranging 
from ‘not satisfied’ to ‘very satisfied.’ Women will also be 
asked to provide a reproductive history and respond to 
questions in relation to each pregnancy that they have 
experienced since the previous survey, including an 
item on whether or not the pregnancy was unintended. 
Figure 1 describes the variables recorded throughout the 
trial to date as well as the proposed 3- year follow- up.
The primary outcome for this longitudinal follow- up is 
the continuation rate of the use of LARCs compared with 
non- LARCs; secondary outcomes include the current 
contraceptive method used; satisfaction with contracep-
tive choice, the number of unintended pregnancies and 
quality of life. Other data collected (see figure 1) will be 
used to investigate mediating variables.
Economic evaluation
The additional longitudinal data will be used to extend 
the economic evaluation of the original 6- month and 
12- month data. An economic evaluation of the orig-
inal data is underway, comparing the intervention and 
control groups in a cost- effectiveness analysis (CEA). The 
perspective used for this analysis is that of the healthcare 
system. Costs include the design and implementation of 
the GP education tool, direct and indirect costs of health 
service use, and the purchase and administration of 
contraceptive products. The outcomes for the economic 
evaluation will be measured in terms of number of LARCs 
inserted, type of contraception chosen, health- related 
quality of life (HRQoL) and quality- adjusted life years 
(QALYs) gained. HRQoL is measured using the 36- Item 
Short Form survey (SF36) and QALYs is estimated using 
the Short Form Six- Dimension health index (SF6D), 
which allows the calculation of QALYs from the SF36 for 
use in the CEA.
Patient and public involvement
Patients were not involved in the consultative process for 
the study design of the ACCORd Study.
Analyses
Description of groups
We will summarise the sociodemographic (age (16–24, 
25–34, 35–44 years), marital status (single, married/
de facto), income (below or above $600 per week) and 
education (completed year 12 or not)) and reproductive 
history (parity, previous abortion, previous unintended 
pregnancy, use of LARC at baseline) characteristics of 
the women from both the intervention and control 
groups who complete the 3- year survey, with counts and 
proportions.
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Figure 1 Variables that were recorded in the initial phase of the study and those that will be recorded for the 3- year 
longitudinal follow- up. LARC, long- acting reversible contraception; STI, Sexually Transmitted Infection.
Outcome evaluation
The association between contraceptive chosen (LARC 
or other method) on the continued use of that contra-
ceptive method will be assessed using binary regression 
models with generalised estimating equations and robust 
standard errors to account for clustering. This analysis 
will allow adjustment for the group to which women were 
randomised as well as sociodemographic and reproduc-
tive history covariates, which will be necessary if there are 
differences between the characteristics of women who 
chose an LARC or other method during the study. This 
approach will also be used to assess which of the study 
(randomised group, contraceptive choice), sociodemo-
graphic (receiving public assistance or difficulty paying 
for basic necessities) and reproductive history covariates 
are associated with the other binary secondary outcomes 
(currently using an LARC; satisfied with contraceptive 
choice (scored >2 on 3- point Likert scale); unintended 
pregnancy since baseline; abortion since baseline). We 
will use multiple imputation and sensitivity analyses to 
explore the impact of missing data.
Economic evaluation
The direct costs of both the intervention and control 
arms will be measured as the costs of consultations with 
GPs and other medical practitioners and the costs of the 
contraceptive products, including their administration, 
where appropriate. Analysis of participants’ Medicare 
(Medicare Benefits Scheme and Pharmaceutical Benefits 
Scheme; MBS and PBS) records will allow for an accurate 
estimate of medical service and pharmaceutical utilisation 
and the associated costs. Indirect costs will be measured in 
terms of travel time and time away from work for women.
The primary outcome for the trial- based CEA will be 
the number of QALYs gained. QALYs will be estimated 
using the SF6D, a classification for describing health 
derived from a selection of SF-36 items. It is composed of 
six multilevel dimensions.
The results of the primary CEA will be reported as 
the cost/QALY gained. Cost- effectiveness will also be 
reported in terms of cost/change in HRQoL (measured 
using the SF-36,12 number of LARC inserted and type of 
contraception chosen). All cost- effectiveness results will 
be presented as net costs and benefits for the interven-
tion arm versus the control arm at 36 months.
The costs of each arm will consider any cost- savings due 
to avoided unintended pregnancies. Mean estimates of 
costs will be used and confidence intervals generated by 
boot- strapping the data. The robustness and validity of 
the CEA will be explored using sensitivity analysis.
A modelled analysis is required to take into account 
costs and outcomes beyond the period of the trial. This will 
be informed by the outcomes and resource use observed 
during the trial, and extrapolated using data from the 
literature and other published sources. In addition to 
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estimating outcomes in terms of QALYs, this analysis will 
also be able to assess the impact of the intervention on 
longer term consequences such as unintended pregnan-
cies avoided and abortions avoided. This analysis will 
enable account to be taken of the long- term impact on 
the resource use and costs associated with LARC (which 
are typically more expensive ‘up- front’ but much less 
expensive over time than SARC), as well as longer term 
impacts such as side effects, discontinuations in contra-
ceptive use (including LARC) and pregnancy rates.
Participant data and study management
All participants in the ACCORd Study (GPs and women) 
were allocated a unique code. Survey data will be recorded 
in a REDCap Database, along with the data from the 
previous surveys. Only ACCORd investigators and the 
project team will have access to this database.
Ethics and dissemination
The initial phase of the ACCORd Study, including the 
recruitment and training of GPs and the recruitment 
and follow- up surveys of the women, received approval 
from the Monash University Human Research Ethics 
Committee: CF16/188-201000080. Approval of an ethics 
amendment to conduct this 3- year longitudinal follow- up 
survey was also received.
The trial follow- up outcomes will be disseminated 
through formal academic pathways, including journal 
articles, national and international conferences and 
reports as well as using more ‘mainstream’ strategies such 
as seminars, workshops and media engagement. Addi-
tionally, outcomes will be communicated through policy 
briefs to Australian state and federal governments. Partic-
ipants will be deidentified for the dissemination of the 
results.
DISCuSSIon
Effective contraception is important in the prevention of 
unintended pregnancies. In Australia, the rates of unin-
tended pregnancies are high, with a national population 
survey finding one in four respondents experienced an 
unintended pregnancy in the past 10 years.13 Moreover, 
the rates of LARC use among Australian women are 
low; just 11% among contraceptive users.14 Given their 
effectiveness13 15 16 and high rates of user satisfaction and 
continuation,5 17 increasing the uptake of LARCs among 
Australian women has been identified as a priority by the 
Australian Healthcare and Hospitals Association.1
The ACCORd intervention addressed a number of 
barriers to LARC uptake in Australia; encouraging women 
to make better informed decisions around their contra-
ceptive choice and enabling timely insertion for women 
who chose an LARC method. The ACCORd intervention 
resulted in an increased uptake of LARCs in the short 
term. Outcomes from the US CHOICE Study provide 
evidence of the long- term effectiveness of an intervention 
for increasing LARC uptake and it is, similarly, important 
to understand whether the effectiveness of the ACCORd 
intervention has been sustained over time.
Comparisons of continuation rates of contracep-
tive method chosen between intervention and control 
groups and a comparison of the number of incidents of 
unintended pregnancy will highlight the importance of 
providing appropriate training to GPs, who are ideally 
placed to provide contraceptive counselling for women 
and encourage sustainable and effective contraceptive 
use.
In addition, an economic evaluation of the study will 
be conducted to determine the cost- effectiveness of 
the intervention. Little is currently known about the 
economic cost of pregnancy or the cost- effectiveness of 
LARC in an Australian context. Recent analysis of inter-
national work on the cost- effectiveness of LARCs has 
assessed the generalisability of these study findings to the 
Australian context, suggesting that LARCs are likely to 
be a cost- effective option within the Australian context.18 
In the US CHOICE Study, despite the extra cost of free 
LARC provision for participants, an increased uptake of 
LARC resulted in considerable cost- savings related to the 
avoidance of unintended pregnancies.19 The economic 
evaluation of the ACCORd Study will consider the cost 
structure of the Australian health system, including reim-
bursement by the MBS and PBS and out- of- pocket costs to 
women. The economic evaluation will highlight whether 
the burden of cost falls to the individuals or to the health-
care system.
The longitudinal results of this follow- up survey, 
including the CEA, will help to further establish the value 
and advantages of interventions aimed at educating GPs 
in effectiveness- based counselling and providing timely 
access to LARC insertion clinics. Findings will make 
important recommendations to improve the current 
Australian system of LARC provision. Moreover, the 
results will contribute to the body of work, both nationally 
and internationally, surrounding interventions and strat-
egies to increase the uptake of LARCs and reduce global 
rates of unintended pregnancy.
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